Prediction of Hepatitis C Recurrence in Liver Transplant Recipients
| Status: | Archived |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2005 |
| End Date: | October 2010 |
The purpose of the study is to look at cells of the immne system to see if the cells are
different among people with different risk factors that have received a liver translant. We
will enroll 50 patients receiving liver transplant and their donors. Both donor and
recipient must participate in the order for the recipient to participate in the study. We
will take blood samples from these patients and their donors.
To establish whether in-vitro donor-specific immune reactivity patterns can differentiate
between those liver transplant recipients who are positive for the Hepatitis C virus (HCV)
who are at high risk and those who are at low risk for graft loss secondary to early
recurrence of HCV.
An assessment of the recipient's donor-specific immune status can be achieved by measuring
T-cell activity, specifically alloreactive primed (donor-specific) T cell activity. It has
been shown that detection of IFN-y in short-term enzyme-linked-immunosorbent-spot (ELISPOT)
assay is consistent with the presence of primed memory T cells (6). In the transplantation
setting, T cells of an allograft recipient that secret IFN-y after short in-vitro exposure
to donor cells represent a prior sensitization of recipient to donor antigens in vivo.
Clinically interpreted - this priming event may signify the presence of an up-coming, or an
on-going, rejection episode. Our limited preliminary data suggest an additional potential
clinical value for the in-vitro assessment of donor-specific IFN-y production in predicting
those liver transplant recipients at higher risk for recurrence of Hepatitis C.
We found this trial at
1
site
Northwestern University Northwestern is recognized both nationally and internationally for the quality of its educational...
Click here to add this to my saved trials
